TA Cloning™ Kit, with pCR™2.1 Vector and One Shot™ TOP10F' Chemically Competent E. coli
TA Cloning&trade; Kit, with pCR&trade;2.1 Vector and One Shot&trade; TOP10F' Chemically Competent <i>E. coli</i>
Invitrogen™

TA Cloning™ Kit, with pCR™2.1 Vector and One Shot™ TOP10F' Chemically Competent E. coli

The TA Cloning™ Kit with pCR™2.1 vector provides a quick, one-step cloning strategy for directly inserting a Taq-amplified PCR productLeia mais
Have Questions?
Alterar visualizaçãobuttonViewtableView
Número do catálogoNo. of Reactions
K20300120 Reactions
K20304040 Reactions
Número do catálogo K203001
Preço (BRL)
5.461,97
Each
Adicionar ao carrinho
No. of Reactions:
20 Reactions
Preço (BRL)
5.461,97
Each
Adicionar ao carrinho
The TA Cloning™ Kit with pCR™2.1 vector provides a quick, one-step cloning strategy for directly inserting a Taq-amplified PCR product into a plasmid vector. The TA Cloning™ Kit uses the pCR™2.1 cloning vector and ExpressLink™ T4 DNA Ligase to generate a ligation product in a fifteen-minute, room-temperature ligation step. Reactions typically yield >80% recombinants containing inserts.

Features of the TA Cloning™ Kit with pCR™2.1 vector:
Fast & convenient—15-minute, room-temperature ligation
Efficient—blue/white screening and >80% clones with correct insert
Flexible—choice of kanamycin or ampicillin resistance for flexible antibiotic selection
Hassle-free—eliminates any enzymatic modifications of the PCR product
Streamlined—does not require the use of PCR primers that contain restriction sites

The pCR™2.1 vector provides:
• 3'-T overhangs for direct ligation of Taq-amplified PCR products
• T7 promoter for in vitro RNA transcription and sequencing
• A versatile polylinker with flanking EcoR I sites for easy excision of inserts
• M13 forward and reverse primer sites for sequencing

How TA Cloning™ Works
Taq polymerase has a non-template-dependent activity that adds a single deoxyadenosine (A) to the 3' ends of PCR products. The linearized vector supplied in this kit has single 3' deoxythymidine (T) residues. This allows PCR inserts to ligate efficiently with the vector.

Kit Configurations
The TA Cloning™ Kit is offered in a variety of configurations: without competent cells (K2020-20 and K2020-40), with One Shot™ INVF' Chemically Competent E. coli (K2000-01 and K2000-40), with One Shot™ TOP10F' Chemically Competent E. coli (K2030-01 and K2030-40), and with One Shot™ TOP10 Chemically Competent E. coli (K2040-01 and K2040-40) in 20- and 40-reaction kit sizes.
For Research Use Only. Not for use in diagnostic procedures.
Especificações
Bacterial or Yeast StrainTOP10F ́
Cell TypeChemically Competent E. coli
Cloning MethodTA Cloning
For Use With (Application)PCR Cloning
No. of Reactions20 Reactions
Product LineOne Shot
Product TypeCloning Kit
PromoterT7
Quantity20 reactions
VectorpCR2.1
FormatKit
Unit SizeEach
Conteúdo e armazenamento
TA Cloning™ kits contain linearized pCR™2.1 vector, ExpressLink™ T4 DNA ligase, 5X ExpressLink™ T4 DNA ligation buffer, dNTPs, 10X PCR buffer, sterile water, and controls. The competent cell kits contain One Shot™ chemically competent E. coli, S.O.C. medium, and a supercoiled control plasmid.

Store One Shot™ E. coli at -80°C. Store all other components at -20°C. All reagents are guaranteed stable for 6 months when properly stored.

Frequently asked questions (FAQs)

Can I use TOP10F' competent cells for transformation of my TOPO vector that contains the ccdB gene?

Strains that contain an F plasmid, such as TOP10F', are not recommended for transformation and selection of recombinant clones in any TOPO vector containing the ccdB gene. While the F plasmid does encode the CcdA protein, which acts as an inhibitor of the CcdB gyrase-toxin protein, the half-life of the CcdA protein is shorter than that of the CcdB protein. Overexpression of the CcdB protein causes cell death when its action is not prevented by sufficient CcdA.

Citações e referências (4)

Citações e referências
Abstract
Xath5 participates in a network of bHLH genes in the developing Xenopus retina [published erratum appears in Neuron 1998 Nov;21(5):following 1221]
Authors:Kanekar S, Perron M, Dorsky R, Harris WA, Jan LY, Jan YN, Vetter ML
Journal:Neuron
PubMed ID:9390513
'We examined the function of basic-helix-loop-helix (bHLH) transcription factors during retinal neurogenesis. We identified Xath5, a Xenopus bHLH gene related to Drosophila atonal, which is expressed in the developing Xenopus retina. Targeted expression of Xath5 in retinal progenitor cells biased the differentiation of these cells toward a ganglion cell fate, ... More
T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
Authors:Carson RT, Vignali KM, Woodland DL, Vignali DA
Journal:Immunity
PubMed ID:9324359
'Naturally processed MHC class II-bound peptides possess ragged NH2 and COOH termini. It is not known whether these peptide flanking residues (PFRs), which lie outside the MHC anchor residues, are recognized by the TCR or influence immunogenicity. Here we analyzed T cell responses to the COOH-terminal PFR of the H-2A(k) ... More
High-performance subtractive hybridization of cDNAs by covalent bonding between specific complementary nucleotides [In Process Citation]
Authors:Ying SY, Lin S
Journal:Biotechniques
PubMed ID:10337490
We have developed an improved subtractive hybridization method that provides a fast, simple and reliable isolation of desired different sequences from two compared DNA libraries, one of which contains all unwanted homologues (subtracter) and another contains certain desired heterologues (tester). The DNA library can be made from either mRNA or ... More
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
Authors: Wei Y Q; Huang M J; Yang L; Zhao X; Tian L; Lu Y; Shu J M; Lu C J; Niu T; Kang B; Mao Y Q; Liu F; Wen Y J; Lei S; Luo F; Zhou L Q; Peng F; Jiang Y; Liu J Y; Zhou H; Wang Q R; He Q M; Xiao F; Lou Y Y; Xie X J; Li Q; Wu Y; Ding Z Y; Hu B; Hu M; Zhang W;
Journal:Proc Natl Acad Sci U S A
PubMed ID:11553767
Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic ... More